Please login to the form below
Incivek
This page shows the latest Incivek news and features for those working in and with pharma, biotech and healthcare.
Leiden reassures on key role at Vertex
The company had been making losses for decades, but had won approval for its oral hepatitis C treatment Incivek (telaprevir) around this time, which became a blockbuster drug for the company.
Latest news
-
Access to new hep C treatments put under the spotlight
It can also be used in patients with advanced liver disease and who have failed prior treatment with HCV protease inhibitors such as Merck &Co's Victrelis (boceprevir) and Vertex' Incivek
-
FDA approves four new medicines across multiple areas
and Vertex' Incivek (telaprevir).
-
J&J starts to feel biosimilar competition bite
toll on J&J's Olysio (simeprevir) and Incivek (telaprevir) products.
-
Top biotech firms saw sales jump in 2014
Dion added: “This drop was largely attributable to sliding sales of Incivek (telaprevir), Vertex's hepatitis C virus protease inhibitor, which fell by $442.3m compared with 2013, primarily as a
-
The end of hepatitis C?
The launch a few years ago of first-generation protease inhibitors to the pharmaco-therapeutic arsenal - Vertex' Incivek (telaprevir) and Merck &Co's Victrelis (boceprevir) - drastically improved success rates in some
More from news
Approximately 0 fully matching, plus 24 partially matching documents found.
Latest Intelligence
-
Vertex: a vision of treating all CF patients worldwide draws closer
a decade of trial and error, the company had a huge breakthrough drug on its hands: hepatitis C treatment Incivek. ... Launched in 2011, Incivek enjoyed the most successful launch in pharma history, earning $1.6bn in sales during its first 12 months on.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Warehousing of HCV patients reaches new high
New drugs from Vertex (Incivek) and Merck (Victrelis) have been welcomed because they are more effective, but they still need to be given with Interferon.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- FDA sets November date for expert panel review of Biogen’s aducanumab
- Moderna CEO says COVID-19 vaccine will be ready for FDA submission in late November
- UK scientists begin testing BCG vaccine for severe COVID-19 protection
- Send Us a Message
- The Truth about Doctors
- Eli Lilly’s COVID-19 antibody trial paused due to safety issue
- Pfizer CEO pushes back COVID-19 vaccine submission to November
- WHO trial casts doubt on remdesivir's efficacy
- Galapagos mid-stage trial failure raises concerns for Gilead deal
- How Far Do You Want To Go?
- Every superhero has an origin story – what’s yours?
- Live Webinar: Solving the Caregiver Crisis Through Technology
PMHub
Fishawack Group of Companies
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...
Latest intelligence
- How Far Do You Want To Go?
- Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…...
- "Fishbowl" Web Meeting for Internal POA Discussions: a Customer Story
- Learn how our client successfully carried out a set of three virtual plan of action (POA) discussions, including one internal “Fishbowl” web meeting....
- Whats the difference between patient engagement and patient experience?
- We all talk a lot about patient engagement and patient experience. And sometimes, these terms are used interchangeably across the industry. But while they’re both important, they’re not the same....
Quick links
Infographics
